Diabetic Neuropathy - Drug Pipeline Landscape, 2023

Diabetic Neuropathy - Drug Pipeline Landscape, 2023

Diabetic neuropathy is a type of nerve damage that can occur in people with diabetes. High blood sugar levels can damage the nerves over time. This type of damage is called neuropathy. Diabetic neuropathy can affect different parts of the body, including the feet, legs, hands, and arms. It can also affect the digestive system, urinary system, blood vessels, and heart. Diabetic neuropathy is a serious complication of diabetes. It can lead to problems with the feet, legs, and hands. It can also lead to problems with the digestive system, urinary system, blood vessels, and heart.

Diabetic neuropathy can cause due to the high blood glucose levels, also called blood sugar, and high levels of fats, such as triglycerides, in the blood from diabetes can damage nerves. High blood glucose levels can also damage the small blood vessels that nourish nerves with oxygen and nutrients.

Symptoms of diabetic neuropathy includes loss of sensation in their feet, burning or shooting pain in their lower legs, muscle weakness or wasting, bladder problems such as incomplete bladder emptying, vision trouble such as double vision.

Doctors most often diagnose diabetic neuropathy by asking about symptoms and physical examination. The tests include filament test, sensory test, nerve conduction test, autonomic test, and electromyography.

The most common investigative treatments include anti-seizure drugs, antidepressants to ease pain. Symptoms can be eased through lifestyle changes and home remedies like physically active, follow diabetes meal plan, quit smoking, and limit alcoholic drinks to no more than one drink per day.

Major pharmaceutical companies are involved in the development of potential drug candidates to improve the Diabetic Neuropathy treatment such as AT-001, VM202, ACY-1215 and others. Key players involved in the development of therapies to treat Diabetic Neuropathy are Applied Therapeutics Inc, AstraZeneca, Celon Pharma SA, Helixmith Co Ltd, Regenacy Pharmaceuticals LLC and others. Two drugs are under late-stage Phase III clinical trials and nine drugs are in Phase II clinical trials and some other drugs are under Phase I and preclinical stages of development.

Report Highlights

Global Insight Service's, Diabetic Neuropathy - Drug Pipeline Landscape, 2023 report provides an overview of the Diabetic Neuropathy pipeline drugs. This report covers detailed insights on Diabetic Neuropathy drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Diabetic Neuropathy pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.

Methodology

The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.

Scope

The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clinical trials, and key upcoming milestones are included.

Reasons to Buy
Helps to find and recognize significant therapeutics under development. Thorough understanding of pipeline structure and helps in developing corrective measures for pipeline projects.
Effective R&D strategies can be developed with deep knowledge of competitor information, analysis, and insights.
Plan collaborations with various industry partners that have role in some or the other stage of drug development such as contract manufacturing, co-development, contract research organization and commercialization etc.
Helps to create in-licensing and out-licensing opportunities by identifying prospective partners with attractive projects to expand business potential and scope.

Please Note: This report will be delivered by publisher within 3-4 business days of order confirmation.